Core Viewpoint - Chengda Biotech's subsidiary has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine aimed at preventing influenza in individuals aged 60 and above [1] Group 1: Company Developments - Chengda Biotech's subsidiary, Chengda Biotech (Benxi) Co., Ltd., has been granted a Clinical Trial Approval Notice for a high-dose influenza vaccine [1] - The vaccine is classified as a Class 3.2 biological product for preventive use, specifically targeting the elderly population [1] Group 2: Market Potential - The effective component of the vaccine is four times the dosage of the standard influenza vaccine, indicating a potentially higher efficacy [1] - The vaccine has already been approved for market use in several countries and regions, suggesting a strong market demand [1]

Core Viewpoint - The approval of a high-dose influenza virus split vaccine by Chengda Biological's subsidiary marks a significant step in addressing the growing demand for influenza prevention among the aging population in China [1][2] Group 1: Vaccine Approval and Characteristics - Chengda Biological's high-dose influenza virus split vaccine has received approval from the National Medical Products Administration to conduct clinical trials [1] - The vaccine is developed using WHO-recommended strains and has an antigen content four times that of standard-dose influenza vaccines, targeting individuals aged 60 and above [1] Group 2: Market Context and Implications - The aging population in China is increasing, leading to a heightened demand for effective influenza prevention strategies among the elderly [2] - Currently, there are no high-dose influenza vaccines approved for sale in China, making this clinical trial approval a crucial step for the company in responding to health aging strategies [2] Group 3: Future Development and Strategic Goals - Chengda Biological aims to continue its innovation-driven development strategy, enhancing its technological platform and the ability to translate research outcomes into products [2] - The company plans to advance the research and development of influenza vaccines and other key projects to improve public health and contribute to the high-quality development of China's biopharmaceutical industry [2]

Group 1 - Company Changda Biological announced that its wholly-owned subsidiary, Changda Biological (Benxi) Co., Ltd., received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] - The approval highlights the long and uncertain development cycle of vaccine products, which may be influenced by various factors [1] Group 2 - Investors should exercise caution and consider investment risks associated with the vaccine development process [1] - Notable investments in the company include a joint investment of 1 billion yuan each from prominent investors Ge Weidong and Fang Wenyuan, leading to a significant increase in the company's stock price [1]

Core Viewpoint - Chengda Biological (688739.SH) has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] Group 1: Company Developments - Chengda Biological's wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., has been granted a clinical trial approval notice for the high-dose influenza virus split vaccine [1] - The vaccine is developed using the influenza virus strains recommended by the World Health Organization (WHO) and contains four times the effective components compared to the conventional dose [1]

Core Viewpoint - Chengda Bio announced that its wholly-owned subsidiary, Chengda Bio (Benxi) Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a high-dose influenza virus split vaccine [1] Group 1: Clinical Trial Approval - The clinical trial approval notification number is 2026LP00405 [1] - The high-dose influenza virus split vaccine is developed using influenza virus strains recommended by the World Health Organization (WHO) [1] - The effective component of the vaccine is four times the dosage of the conventional influenza vaccine [1]

Group 1: Fundraising Overview - The company raised a total of RMB 4,581,500,000 through its initial public offering, with a net amount of RMB 4,341,379,433.74 after deducting issuance costs [2] - The funds were deposited into a special account for management and were subject to a tripartite supervision agreement with the sponsor and the bank [2][3] Group 2: Fund Allocation and Project Adjustments - The company decided to terminate five research sub-projects and reallocate the unused funds to other ongoing and new sub-projects, including an investment of RMB 10 million to its wholly-owned subsidiary for a new flu vaccine project [3] - A special account was established for the "high-dose flu virus split vaccine" project, adhering to the principle of "special account storage and special fund usage" [4] Group 3: Tripartite Supervision Agreement - The tripartite agreement involves the company, its subsidiary, and the bank, ensuring that the funds are used exclusively for the designated project [5] - The agreement stipulates that any withdrawal exceeding 20% of the net fundraising amount must be reported to the sponsor within five working days [7] Group 4: Share Buyback Progress - The company plans to repurchase shares using between RMB 10 million and RMB 20 million of surplus funds, with a maximum price of RMB 38.00 per share [11] - As of December 31, 2025, the company had repurchased 384,899 shares, accounting for approximately 0.092% of the total share capital, with a total expenditure of RMB 10,789,216.56 [13]

Core Viewpoint - Liaoning Chengda Biological Co., Ltd. has announced the termination of its "Hib vaccine" development, marking the sixth vaccine project termination this month, amidst increasing competition in the domestic vaccine market and challenges including declining core product revenues, a shrinking R&D pipeline, and three consecutive years of declining performance [1][7]. Strategic Shift - Chengda Biological has terminated six projects in January, shifting its R&D focus towards combination vaccines. The company raised net funds of 4.341 billion yuan during its 2021 IPO, planning to cover 20 sub-projects under "human vaccine R&D." However, as of October 31, 2025, only 482 million yuan has been invested, with recent terminations attributed to intense market competition, insufficient product differentiation, and unclear commercialization prospects for some projects [2][8]. - The company is reallocating resources towards high-value projects such as the "high-dose influenza virus split vaccine" and "high-priced pneumococcal polysaccharide conjugate vaccine," indicating a strategic shift from broad coverage to focused breakthroughs on products with higher market potential [2][8]. Core Product Pressure - Chengda Biological has heavily relied on its human rabies vaccine, which accounted for over 93% of total revenue from 2020 to 2023. However, its market share has plummeted from 73.08% in 2019 to 36.29% in 2024, while the product price has dropped significantly from 215.6 yuan per dose in 2020 to approximately 61.18 yuan in 2024 [3][9]. - The presence of 23 marketed human rabies vaccines and 19 in clinical stages has intensified competition, leading to widespread price-cutting strategies among companies. The risk of a single product structure, previously highlighted in the company's prospectus, is now materializing [3][9]. Financial Performance Decline - Chengda Biological's financial performance has deteriorated since 2022, with revenue dropping from 1.815 billion yuan in 2022 to 1.675 billion yuan in 2024, and net profit shrinking from 714 million yuan to 343 million yuan during the same period [4][10]. - In the first three quarters of 2025, the company reported a 15.88% year-on-year revenue decline and a significant 50.01% drop in net profit, attributing these changes to intensified competition in the domestic vaccine market [4][10]. Conclusion - Chengda Biological is currently facing pressures from stagnant growth of its flagship product, a strategic contraction in its R&D pipeline, and ongoing performance declines. The company's attempts to pivot towards combination vaccines and high-priced products in response to market challenges are fraught with uncertainty, making the success of new product development a key focus for investors [5][11].